Provision of over-encapsulated Sitagliptin (Januvia), Pioglitazone (Actos) and Cangliflozin (Invokana) for a double-blind randomised clinical trial
What the buyer wrote
The University of Exeter is seeking a suitable and capable provider of investigational medicinal product for use by its Medical School as part of a diabetes clinical trial. The Unviersity of Exeter Medical School is undertaking a MRC-funded study aiming to develop a stratified approach in Type 2 diabetes that will result in more effective use of glucose lowering therapy. The Trimaster trial, sponsored by the Royal Devon & Exeter NHS Foundation Trust (RD&E FT) is a randomised double-blind Cross-Over trial of three standard diabetes therapies, a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in 600 patients with type 2 diabetes. It aims to directly test potential s…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Provision of over-encapsulated Sitagliptin (Januvia), Pioglitazone (Actos) and Cangliflozin (Invokana) for a double-blind randomised clinical trial
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- goods
- Work starts
- 21 Sep 2015
- Work ends
- 31 Jul 2019
- Kind of work
- Pharmacy and medicines
Who the buyer named
Sam Barker was the named contact on this notice.